Aarey Drugs & Pharmaceuticals Ltd

Unaudited results

• Unaudited standalone quarterly results for quarter ended 30 June 2026 approved.
• Limited Review Report and MD/CFO certification approved.

Funds deviation from convertible warrants

• Statement of deviation/variation approved; pertains to convertible warrants issued as preferential issue.
• Nil deviation for the quarter; no funds received in quarter as per note.
• Date of allotment 23/05/2025 and amount Rs 797.50 lakhs.

Auditor review status

• Independent auditor's review states no material misstatement in results.

Regulatory/compliance update

• Trading window to reopen 48 hours after results announcement.

Meeting Details

• Board meeting scheduled for Friday, 14 August 2026.
• Time and venue not disclosed.

Key Agenda Items

• Unaudited standalone financial results with Limited Review for quarter ended 30 June 2026.
• Any other matter with consent of the Chairman.

Other Notes

• Trading window closed from July 1, 2026 until 48 hours after results announcement.

Demat processing status

• Dematerialisation requests processed by the Registrar and Share Transfer Agent; confirmations issued to the depositories.
• Securities dematerialised were listed on the exchanges where the previously issued securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled after verification; depository name substituted as registered owner within timelines.

Meeting Details

• Board meeting scheduled for Friday, 29 May 2026.

Key Agenda Items

• Approve audited financial results and auditors' report for quarter and year ended 31 March 2026.

Other Notes

• Trading window for designated persons is already closed and reopens 48 hours after results announcement.